期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

FES PET-CT成像与乳腺癌诊疗 被引量：4

FES PET-CT imaging in breast cancer
下载PDF
导出
摘要 FES PET-CT显像在乳腺癌中的临床应用是通过FES与功能性雌激素受体(ER)特异结合特性,利用标准摄取值半定量地、客观地反映了患者活体内功能性ER的分布及其生物活性,判断乳腺肿瘤原发灶及转移灶、治疗前后肿瘤组织ER表达的异质性,对乳腺癌内分泌治疗提供依据。FES与FDG PET-CT对比显像提供的乳腺肿物定性、定量、定位及生物学行为的信息,能更好地对乳腺癌患者进行疗效评价和预后分析,给乳腺癌诊疗带来划时代的意义。 In the clinical application of breast cancer,FES PET-CT imaging,which is through its specific binding to functional estrogen receptors（ERs）,semi-quantitatively and objectively reflects the distribution and biological activity of ERs by standard uptake value and detects the heterogeneity of ERs expression between primay lesions and metastases,lesions before treatments and ones after treaments in order to provide the basis of endocrine therapy of breast cancer.FES/FDG PET-CT compared imaging provides information about qualitation,quantitation,location and the biological behavior of breast tumor to evaluate the therapeutic efficacy and prognosis of breast cancer patients,and brings epoch-making significance to diagnosis and treatment of breast cancer.
作者 杨欢 陈晓耕
机构地区 福建医科大学省立临床医学院肿瘤外科 福建省立医院肿瘤外科
出处 《现代肿瘤医学》 CAS 2012年第2期412-416,共5页 Journal of Modern Oncology
关键词 (18F)FES 正电子发射断层扫描 乳腺癌 （18F）FES PET scan breast cancer
分类号 R737.9 [医药卫生—肿瘤]
  • 相关文献

参考文献43

  • 1陈道宝,杨红健.乳腺癌ER与FES-PET[J].中国肿瘤,2008,17(7):588-592. 被引量：7
  • 2Tewson TJ,Mankoff DA,Peterson LM,et al.Interactions of 16alpha-[18F]-fluoroestradiol(FES)with sex steroid binding protein(SBP)[J].Nucl Med Biol,1999,26:905-913.
  • 3Kiesewetter DO,Kilbourn MR,Landvatter SW,et al.Preparation of four fluorine-18-labeled estrogens and their selective uptakes in target tissues of immature rats[J].J Nucl Med,1984,25:1212-1221.
  • 4Pan CC,Woolever CA,Bhavnani BR.Transport of equine estrogens:binding of conjugated and unconjugated equine estrogens with human serum proteins[J].J Clin Endocrinol Metab,1985,61,499-507.
  • 5Petra P.The plasma sex steroid binding protein(SBP or SBHG):a critical review of recent developments on the structure,molecular biology and function[J].J Steroid Biochem Mol Biol,1991,40:735-753.
  • 6Jonson SD,Bonasera TA,Dehdashti F,et al.Comparative breast tumor imaging and comparative in vitro metabolism of 16alpha-[18F]?uoroestradiol-17beta and 16beta-[18F]?uoromoxestrol in isolated hepatocytes[J].Nucl Med Biol,1999,26:123-130.
  • 7Mankoff DA,Tewson TJ,Eary JF.Analysis of blood clearance and labeled metabolites for the estrogen receptor tracer[F-18]-16 alpha-fluoroestradiol(FES)[J].Nucl Med Biol,1997,24:341-348.
  • 8Sundararajan L,Linden HM,Link JM,et al.18F-Fluoroestradiol[J].Semin Nucl Med,2007,37(6):470-476.
  • 9Mathias CJ,Welch MJ,Katzenellenbogen JA,et al.Characterization of the uptake of 16 alpha-([18F]fluoro)-17 beta-estradiol in DMBA-induced mammary tumors[J].Int J Rad Appl Instrum B,1987,14(1):15-25.
  • 10Mankoff DA,Peterson LM,Tewson TJ,et al.[18F]fltuoroestradiol radiation dosimetry in human PET studies[J].J Nucl Med,2001,42:679-684.

二级参考文献30

  • 1江泽飞,徐兵河,宋三泰,孙燕.乳腺癌内分泌治疗的基本共识[J].中华肿瘤杂志,2006,28(3):238-239. 被引量：48
  • 2贾丽,于金明,王仁本,巩合义,李金丽,焦玉红.^(18)F-FDG PET/CT对乳腺癌新辅助化疗疗效预测的价值[J].中国肿瘤临床与康复,2006,13(3):215-218. 被引量：10
  • 3赵婷婷,李继光,李亚明.^18 F-FDG PET／CT对原发性乳腺癌诊断和淋巴结分期的临床价值[J].中华肿瘤杂志,2007,29(3):206-209. 被引量：6
  • 4Althuis MD, Fergenbaum JH, Garcia-Closas MG. Etiology of hormone receptor-defined breast cancer:A systematic leview of the literature [J]. Cancer Epidemiol Biomarkers Prey, 2004, 13(10):1558-1568.
  • 5Early Breast Cancer Trialst's Collaborative Group (EBCTCG).Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of randomized trials[J]. Lancet, 2005, 365(9472): 1687-1717.
  • 6Coates AS, Keshaviah A, Thtirlimann B, et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98[J]. J Clin Oncol, 2007, 25(5):486-492.
  • 7Forbes JF, Cuzick J, Buzdar A, et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial[J]. Lancet Oncol, 2008, 9(1):45-53.
  • 8Mouridsen H, Gershanovich M, Sun Y, et al. Superior efficacy of letrozole verus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: result of a phase Ⅲ study of the international Letrozole Breast Cancer Group [J]. J Clin Oncol, 2001, 19(10): 2596-2606.
  • 9Fisher B, Wang J, Bryant J, et al. Pathobiology of preoperative chemotherapy: finding from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18 [J]. Cancer, 2002, 20(12):2905-2907.
  • 10Bear HD, Anderson S, Smith RE. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project protocol B-27[J]. J Clin Oncol, 2006, 24(13):2019.

共引文献6

同被引文献50

  • 1<乳腺癌HER2检测指南>编写组,霍临明.乳腺癌HER2检测指南[J].中华病理学杂志,2006,35(10):631-633. 被引量：163
  • 2王书昌,杨学伟,张玉玲.乳腺癌中Survivin和VEGF的表达[J].现代医学生物进展,201l,11(21):4159-4162.
  • 3Turner N, Pearson A, Sharpe R, et al. FGFR1 amplification drives en docrine therapy resistance and is a therapeutic target in breast cancer [J]. Cancer Res,2010,70(5) :2085-2094.
  • 4Altieri DC. Survivin,cancer networks and pathway-directed drug discovery[J]. Nat Rev Cancer, 2008,8 (1) : 61-70.
  • 5Li F, Ling X. Survivin study: an update of "what is the next wave"? [J]. J Cell Physiol,2006,208(3) :476-486.
  • 6Weiss J,Sos ML,Seidel D,et al. Frequent and focal FGFR1 am- plification associates with therapeutically tractable FGFR1 de- pendency in squamous cell lung cancer[J]. Sci Transl Med, 2010, 2 (62) : 62ra93.
  • 7Devilard E,Bladou F,Ramuz O,et al. FGFR1 and WT1 are markers of human prostate cancer progression[J]. BMC Cancer, 2006,6: 272.
  • 8Tsimafeyeu I, Demidov L, Stepanova E, et al. Overexpression of fibroblast growth factor receptors FGFR1 and FGFR2 in renal cell carcinoma[J]. Seand J Urol Nephrol,2011,45(3) ; 190-195.
  • 9Freier K, Schwaenen C, Sticht C, et al. Recurrent FGFR1 amplifi- cation and high FGFR1 protein expression in oral squamous cell carcinoma(OSCC) [J]. Oral Oncol, 2007,43 (1) : 60-66.
  • 10Elbauomy Elsheikh S, Green AIR, Lambros MB, et al. FGFR1 ampli- fication in breast carcinomas:a chromogenic in situ hybridisation anal- ysis[J]. Breast Cancer Res, 2007,9 (2) :R23.

引证文献4

二级引证文献5

现代肿瘤医学
2012年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部